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Background: Comorbidity, such as diseases of the cardiovascular, 
pulmonary, and other systems, may influence prognosis in lung can-
cer and complicate its treatment. The performance status of patients, 
which is a known prognostic marker, may also be influenced by 
comorbidity. Due to the close link between tobacco smoking and 
lung cancer, and because lung cancer is often diagnosed in advanced 
ages (median age at diagnosis in Denmark is 70 years), comorbidity 
is present in a large proportion of lung cancer patients.
Methods: Patients with any stage lung cancer who did not have 
surgical treatment were identified in the Danish Lung Cancer 
Registry. Danish Lung Cancer Registry collects data from clinical 
departments, the Danish Cancer Registry, Danish National Patient 
Registry, and the Central Population Register. A total of 20,552 
patients diagnosed with lung cancer in 2005 to 2011 were identified. 
Comorbidity data were extracted from the Danish National Patient 
Registry, which is a register of all in- and outpatient visits to hospi-
tals in Denmark. By record linkage, lung cancer patients who had 
previously been diagnosed with comorbid conditions were assigned a 
Charlson comorbidity index. Initial cancer treatment was categorized 
as chemotherapy, chemoradiation, radiotherapy, or no therapy. Data 
on Charlson comorbidity index, performance status, age, sex, stage, 
pulmonary function (forced expiratory volume in 1 second), histol-
ogy, and type of initial treatment (if any) were included in univariable 
and multivariable Cox proportional hazard analyses.
Results: Treatment rates for chemotherapy and chemoradiation 
declined with increasing comorbidity and in particular increasing 
age. Women received treatment more often than men. In a univari-
able analysis of all patients combined, stage, performance status, age, 
sex, lung function, and comorbidity were all associated with survival. 
Apart from excess mortality among patients with unspecified histo-
logical subtypes (hazard ratio), there was no clear difference between 
the specified subtypes. When adjusting for the other factors, partic-
ularly age, sex, performance status, and stage proved to be robust 
while risk estimates for comorbidity were attenuated somewhat. 
When grouped by the three types of cancer treatment or no treatment, 
there was no influence of comorbidity on radiation therapy and mod-
est influence on survival after chemotherapy and chemoradiation. In 
contrast, age remained a strong negative prognosticator after multi-
variate adjustment as did stage and performance status.
Conclusion: Comorbidity has a limited effect on survival and only 
for patients treated with chemotherapy. It is rather the performance of 
the patient at diagnosis than the medical history that prognosticates 
survival in this patient group.
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(J Thorac Oncol. 2015;10: 272–279)
The simultaneous presence of cancer and other medical conditions (comorbidity) is frequent. Cigarette smoking is 
the major risk factor for lung cancer (LC), and other tobacco-
related diseases are particularly frequently found in patients 
with LC.1 Comorbidity affects outcome in several ways, such 
as reluctance toward diagnosis and therapy and impaired tol-
erance to treatment.2,3 Furthermore, comorbidity may affect 
the performance status (PS) of the individual, thereby reduc-
ing the efficacy and increasing the side effects of treatment. 
Anticancer treatment may worsen a number of common 
comorbid conditions such as diabetes and kidney failure, 
and comorbid diseases may directly shorten life expectancy. 
Comorbidity has been shown to be associated with subopti-
mal chemotherapy and with poor survival in clinical trials, 
and guidelines recommend that comorbidity be considered 
when planning treatment for patients with LC.4,5 In general, 
outcome of therapy is dependent on multiple factors, which in 
LC includes sex, stage, age, and PS. However, the magnitude 
of the effect of comorbidity and the interaction with PS and 
age are unknown, and we therefore conducted this study to 
determine the role of comorbidity on treatment rates and sur-
vival for patients with advanced (nonsurgical) LC.
METHODS
Newly diagnosed patients with LC were identified 
in the Danish Lung Cancer Registry for the period 2005 to 
2011. The register covers all hospital departments in Denmark 
and collects information on diagnostic procedures, stage, 
Eastern Cooperative Oncology Group PS, and first treatment.6 
This information was supplemented by record linkage to 
the Central Population Register for information on survival, 
DOI: 10.1097/JTO.0000000000000416 
Copyright © 2014 by the International Association for the Study of Lung Cancer
ISSN: 1556-0864/15/1002-0272
Role of Comorbidity on Survival after Radiotherapy and 
Chemotherapy for Nonsurgically Treated Lung Cancer
Anders Mellemgaard, MD, PhD,* Margreet Lüchtenborg, MSc, PhD,† Maria Iachina, PhD,‡  
 Erik Jakobsen,  MD, MPH,‡ Anders Green, MD, PhD,‡ Mark Krasnik,§ and  Henrik Møller, DrMedSci†
*Herlev University Hospital, Copenhagen, Denmark; †Cancer Epidemiology 
and Population Health, King’s Health Partners Cancer Centre, London, 
United Kingdom; ‡Odense University Hospital, Odense, Denmark; and 
§Gentofte University Hospital, Gentofte, Denmark.
Disclosure: The authors declare no conflicts of interests.
Address for correspondence: Anders Mellemgaard, MD, PhD, Herlev University 
Hospital, Herlev Ringvej 75, Herlev dk-2730, Denmark. E-mail: anders.
mellemgaard@regionh.dk
ORIGINAL ARTICLE
273Copyright © 2014 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 10, Number 2, February 2015 Role of Comorbidity on Lung Cancer Patient
the National Pathology Register for pathology information, 
and the National Patient Registry for information on previ-
ous illnesses.7,8 The latter register contains coded discharge 
diagnosis and interventions related to diagnostic evaluation 
and treatment for all somatic patient admissions in Denmark. 
Information on comorbidity was included up to 10 years 
before LC diagnosis. Comorbidity was classified according 
to the scores from the weighted Charlson comorbidity index 
(CCI), however, leaving out information on cancer-related 
contact within 150 days before the date of LC diagnosis.9 If 
an individual had a disease coded more than once with a dif-
ference in severity (uncomplicated versus complicated or mild 
versus severe), the most severe score was used. The CCI is an 
extensively validated comorbidity measure and is calculated 
from 19 different disorders, which can be grouped in seven 
broader groups.
Patients were categorized in four age groups based on 
age at diagnosis. Lung function was based on forced expira-
tory volume in 1 second (FEV
1
) as percentage of predicted 
value and grouped in four groups. Clinical stage was based on 
clinical information on tumor, lymph nodes, and metastasis 
(TNM) and recoded according to the seventh edition of TNM. 
The nonsurgical treatment was coded as no treatment, chemo-
therapy only, radiotherapy only, or chemoradiation. Only the 
initial treatment was considered.
Multivariable logistic regression was used to calcu-
late odds ratio (OR) and 95% confidence intervals for hav-
ing chemo- or radiotherapy and chemoradiation according to 
comorbidity and age, sex, stage, histological subtype, FEV
1
, 
and PS. Univariable and multivariable Cox proportional haz-
ard analyses were used to calculate hazard ratios (HRs) and 
95% confidence intervals for survival of the various catego-
ries. χ2 tests were used to estimate the p value for trend and 
heterogeneity, excluding missing value categories.
RESULTS
A total of 20,552 patients were identified, four had miss-
ing data on comorbidity and were excluded leaving 20,548 for 
the analysis. Slightly more men than women were included 
(53% versus 47%), and the median age at diagnosis was 69 
years. For some variables, there were missing data: lung func-
tion (FEV
1
) was missing for 35%, for cTNM 14% was miss-
ing, and histological subtype was missing for 14% of patients 
(Table 1).
Of the 20,548, 10,270 (50%) had no comorbidity (CCI 
= 0), 4727 (23%) had a CCI of 1, 3359 (16%) had a CCI of 2, 
and 2192 (11%) had a CCI of 3 or more. Comorbid conditions 
and thus CCI appeared to increase with age although low CCI 
was found in the oldest age group of 80 years or older. The 
majority of patients had advanced stage disease IIIa (14%), 
IIIB (13%), and IV (46%). Adenocarcinoma was the most 
frequent histology (26%) although the number of patients 
in unspecified categories of non–small-cell lung cancer was 
high (31%). The most frequent type of initial treatment was 
radiotherapy (33%) followed by chemotherapy (17%) and 
chemoradiation (13%). No treatment was recorded as initial 
treatment for 7563 (37%) patients (Table 1). Frequencies of 
the various comorbid conditions are shown in Table 2. The 
most frequent comorbidity was chronic obstructive lung dis-
ease found in 10% in LC patients. Also, a history of another 
cancer than LC was observed in a substantial number (9%).
Table 3 presents ORs for having a specific treatment 
in relation to CCI, age, and sex, and further adjusted for PS, 
FEV
1
, stage, and histology. With increasing CCI, the odds of 
having radiotherapy and especially chemotherapy and chemo-
radiation was significantly reduced. For patients with a CCI of 
3 or more, the ORs of having chemotherapy or chemoradia-
tion were 0.54 or 0.61, respectively. For patients older than 
70 years, the odds of having chemotherapy or chemoradia-
tion was significantly reduced to such a degree that the ORs 
for having chemotherapy or chemoradiation for those aged 
80 years or more were 0.11 and 0.10 compared with patients 
younger than 60 years. A slight difference was found for sex 
with higher chemotherapy and chemoradiation treatment 
rates for women. In Table 4, odds of receiving radiotherapy 
is shown by intent of treatment. CCI significantly affected the 
odds of having curative but not palliative radiotherapy.
Survival was highly influenced by CCI with increas-
ingly poor survival for patients with comorbidity (p for trend 
< 0.001; Table 5). However, after multivariable adjustment, 
the difference was attenuated so that the HR for CCI of 3 or 
more of 1.31 in the univariable analysis was reduced to an 
HR of 1.10 in the multivariable analysis. Likewise, a strong 
negative impact of age on survival was found although attenu-
ated when controlled for other factors. Women had a signifi-
cantly better survival than men (HR
univariable
 = 0.87), and this 
difference was actually more pronounced in the multivariable 
model (HR
multivariable
 = 0.81). PS was strongly associated with 
survival (p for trend < 0.001), so that patients with a PS of 
4 had an HR
univariable
 of 6.54, which was somewhat reduced 
when adjusted for other factors (HR
multivariable
 = 4.31). Some 
histological subtypes were found to be associated with higher 
death rates compared with adenocarcinoma, non–small-cell 
LC, large cell, and not otherwise specified and unknown sub-
type LC with HR
univariable
 of 1.27, 1.19, and 1.36, respectively. 
These estimates were attenuated but remained significant 
after adjustment for other factors. Finally, as expected, stage 
was a very strong and robust indicator for survival. HR
univariable
 
for survival increased gradually up to 4.09 for stage IV (p
trend
 
<0.0001). The estimates remained virtually unchanged after 
adjustment.
Table 6 examines HR for survival for the three treatment 
categories by CCI and the other main prognostic factors: age, 
sex, PS, and stage. For patients with radiotherapy as initial 
treatment, there was actually a trend toward better survival 
for increasing comorbidity (p
trend
 = 0.09) and higher age (p
trend
 
= 0.003). Again, a significantly better survival was seen in 
women. Conversely, a worse survival was seen with poor PS 
and higher stages. Although stage remained very robust after 
adjustment, somewhat attenuated HRs were seen when PS was 
adjusted. For chemotherapy, there was a clear trend for poor 
prognosis being associated with high degree of comorbidity, 
age, PS, and stage (p
trend
 ≤ 0.001 for all variables). As earlier, 
women had better survival than men. For chemoradiation, a 
modest effect of comorbidity (p
trend
 = 0.44) and age (p
trend
 = 
0.02) was found. Advanced PS and stage were highly strongly 
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TABLE 1.  Prognosic Factors by Charlson Comorbidity Score
Total
Charlson Comorbidity Score
0 1 2 3+
Number % Number % Number % Number % Number %
All patients 20,548 100 10,270 100 4727 100 3359 100 2192 100
Age (yr)
  <60 3907 19 2620 26 687 15 426 13 174 8
  60–69 6703 33 3549 35 1546 33 1043 31 565 26
  70–79 6994 34 2978 29 1784 38 1293 38 939 43
  80+ 2944 14 1123 11 710 15 597 18 514 23
Sex
  Male 10,872 53 5278 51 2418 51 1864 55 1312 60
  Female 9676 47 4992 49 2309 49 1495 45 880 40
ECOG performance status
  0 4685 23 2984 29 878 19 548 16 275 13
  1 6000 29 3054 30 1401 30 946 28 599 27
  2 3366 16 1489 14 844 18 599 18 434 20
  3 2046 10 780 8 564 12 405 12 297 14
  4 995 5 348 3 259 5 222 7 166 8
  Unknown 3456 17 1615 16 781 17 639 19 421 19
FEV
1
 (% pred)
  >81 3947 19 2295 22 755 16 555 17 342 16
  66–81 2757 13 1520 15 591 13 402 12 244 11
  51–65 2982 15 1592 16 666 14 448 13 276 13
  ≤50 3668 18 1492 15 1050 22 647 19 479 22
  Unknown 7194 35 3371 33 1665 35 1307 39 851 39
cTNM stage
  Ia 609 3 208 2 170 4 133 4 98 4
  Ib 1075 5 498 5 259 5 165 5 153 7
  IIa 386 2 183 2 88 2 63 2 52 2
  IIb 678 3 337 3 153 3 109 3 79 4
  IIIa 2868 14 1377 13 676 14 485 14 330 15
  IIIb 2670 13 1440 14 611 13 375 11 244 11
  IV 9441 46 4896 48 2152 46 1487 44 906 41
  Unknown 2821 14 1331 13 618 13 542 16 330 15
Histological type
  Adenocarcinoma 5405 26 2806 27 1117 24 883 26 599 27
  Non-small cell 1763 9 987 10 413 9 230 7 133 6
  Small cell 2684 13 1389 14 658 14 416 12 221 10
  Large cell 554 3 309 3 121 3 90 3 34 2
  Squamous cell 3571 17 1588 15 868 18 634 19 481 22
  Carcinoid 42 0 26 0 8 0 5 0 3 0
  Other specified 91 0 44 0 25 1 13 0 9 0
  Unspecified 3529 17 1730 17 732 15 622 19 445 20
  Unknown 2909 14 1391 14 785 17 466 14 267 12
Initial treatment
  None 7563 37 3133 31 1855 39 1465 44 1110 51
  Chemotherapy 3443 17 1569 15 805 17 616 18 453 21
  Radiotherapy 6773 33 3871 38 1462 31 968 29 472 22
  Chemoradiation 2769 13 1697 17 605 13 310 9 157 7
cTNM, clinical tumor, lymph nodes and metastasis; ECOG, Eastern Cooperative Oncology Group; FEV
1
, forced expiratory volume in 1 second.
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TABLE 2.  Individual Comorbid Conditions According to Age Category
Comorbidity Total
Age Category (yr)
<60 60–69 70–79 80+
n % n % n % n %
20,548 3907 19 6703 33 6994 34 2944 14
Myocardial infarct 245 30 12 74 30 90 37 51 21
Congestive heart failure 286 24 8 66 23 115 40 81 28
Peripheral vascular disease 743 64 9 245 33 321 43 113 15
Cerebrovascular disease 951 119 13 318 33 352 37 162 17
Dementia 98 5 5 21 21 42 43 30 31
Chronic lung disease 2658 322 12 772 29 1124 42 440 17
Connective tissue disease 562 97 17 185 33 211 38 69 12
Ulcer 604 75 12 175 29 233 39 121 20
Chronic liver disease 151 54 36 62 41 29 19 6 4
Diabetes 663 83 13 216 33 259 39 105 16
Hemiplegia 36 9 25 17 47 8 22 2 6
Moderate or severe kidney disease 293 29 10 80 27 110 38 74 25
Diabetes with end organ damage 606 72 12 209 34 236 39 89 15
Tumor 1874 214 11 544 29 709 38 407 22
Leukemia 78 9 12 20 26 30 38 19 24
Lymphoma 171 25 15 51 30 67 39 28 16
Moderate or severe liver disease 60 20 33 26 43 11 18 3 5
Metastasis 182 31 17 62 34 68 37 21 12
AIDS 17 5 29 11 65 1 6 0 0
None 10,270 2620 26 3549 35 2978 29 1123 11
TABLE 3.  Odds Ratio for Receiving Cancer Treatment by Comorbidity Score, Age, and Sex
Radiotherapy Chemotherapy Chemoradiation
Odds Ratio 95% CI Odds Ratio 95% CI Odds Ratio 95% CI
Charlson score
  0 1.00 1.00 1.00
  1 0.96 0.89–1.03 0.85 0.78–0.92 0.92 0.83–1.03
  2 0.85 0.78–0.93 0.70 0.64–0.77 0.67 0.59–0.77
  3+ 0.89 0.80–0.99 0.54 0.48–0.61 0.61 0.51–0.73
  χ2 12.00 0.0005 140.53 <0.0001 51.45 <0.0001
Age (yr)
  <60 1.00 1.00 1.00
  60–69 0.95 0.87–1.03 0.88 0.80–0.96 0.84 0.76–0.93
  70–79 0.87 0.80–0.96 0.51 0.46–0.55 0.50 0.45–0.56
  80+ 0.82 0.73–0.92 0.11 0.09–0.13 0.10 0.08–0.14
  χ2 15.82 0.0001 1090.67 <0.0001 388.41 <0.0001
Sex
  Male 1.00 1.00 1.00
  Female 1.05 0.98–1.12 1.10 1.03–1.18 1.14 1.04–1.25
  χ2 2.05 0.15 7.33 0.01 7.22 0.01
Multivariable models are adjusted for variables shown, and ECOG performance status, lung function (FEV
1
 %predicted), stage and histological type. χ2 for trend or heterogeneity, 
where appropriate.
CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; FEV
1
, forced expiratory volume in 1 second.
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associated with poor survival with HR
univariable
 for PS of 4 and 
stage IV of 2.49 and 2.54, respectively.
DISCUSSION
The CCI appeared to increase with age although low 
CCI was found in the oldest age group of 80 years or older. 
This could indicate some degree of nihilism among patients or 
health professionals regarding diagnostic work-up among the 
very old, leaving the fit elderly for diagnostic work-up. With 
increasing CCI, a decrease in odds of having chemotherapy 
and chemoradiation was found, but for radiotherapy, this asso-
ciation was only seen for treatment with curative intent.
CCI was a modest prognostic factor for survival of 
LC, and risk estimates for comorbidity were attenuated when 
controlled for other factors such as PS and stage. Conversely, 
stage, sex, and PS were strong prognostic factors and were 
robust to adjustment. This indicates that it is the PS at diagno-
sis rather than the history of comorbid conditions that affects 
the outcome for LC patients. The data used in this study are 
of high quality. There is no private sector for cancer diagno-
sis or treatment in Denmark, and health care is provided for 
free, including cancer medication. Therefore, all patients are 
in public disease registers. Records held by The Danish Lung 
Cancer Registry are cross-checked with other disease register 
such as the Cancer Registry and are estimated to be virtually 
complete.6 The central population register includes the total 
Danish population and is updated daily. All pathology data 
are kept at the Pathology Register. The information on comor-
bidity that we have used is derived from the National Patient 
Register that keeps records for all contacts (in- or outpatient) 
to Danish hospitals. For each contact, information on primary 
and secondary diagnosis and date are recorded.7 Linkage 
between registers is carried out using a unique personal iden-
tifier, and there is thus no loss to follow-up. To ascertain the 
presence of comorbid conditions, we retrieved all informa-
tion on relevant diagnosis to construct the CCI. Although CCI 
includes grading for some conditions, more exact information 
regarding the severity of most or treatment for comorbid con-
ditions was not available. A record, of, say diabetes mellitus 
with complications, thus indicates the presence of this con-
dition but not whether this condition actually influenced the 
patient’s performance or ability to tolerate treatment. As this 
represent nondifferential misclassification, the true effect of 
comorbidity may actually be larger than what we have found. 
We analyzed CCI as an indicator of comorbidity but not the 
individual diseases that are included in the CCI.
Throughout the analysis, PS was a stronger and more 
robust risk factor than CCI. It is important to note that CCI 
was based on medical history while PS was determined at 
the time of diagnosis by the pulmonologist. These two fac-
tors are closely linked because comorbidities may contribute 
to decreased PS. The mutual adjustment of one for the other 
in a multivariate analysis may indicate which factor is most 
important, but the effects cannot be completely separated. Our 
finding that low lung function was associated with a poorer 
survival corroborates observations from other studies.10 A nor-
mal lung function is usually required for curative chemoradia-
tion. For palliative treatment, a reduced lung function would 
render the patient more susceptible to complications such as 
pneumonia. Also, a poor lung function would in many cases 
have a negative impact on PS. Not all comorbid conditions are 
equally harmful. Diabetes may provide the exception as this 
comorbid condition may actually improve prognosis although 
data are conflicting.11,12 It has been suggested that CCI may 
not be the best measure of comorbidity because it does not 
necessarily capture the relevant comorbidities.13 Some comor-
bidities that may be important for choice of systemic treat-
ment in LC such as polyneuropathy and benign hematologic 
conditions are not part of the score basis for CCI.
Factors such as stage, PS, patient preferences, and 
comorbidity are considered when a treatment plan is made 
for an individual patient. It is therefore not surprising that the 
rate of treatments that are difficult to tolerate such as chemo-
therapy and in particular chemoradiation are lower in the more 
comorbid patients. We found that treatment was given less 
frequently to older age groups, perhaps because it is known 
that the risk of side effects are greater in the older LC popula-
tion. The odds that women receive chemotherapy and chemo-
radiation are higher than in men. This may partially explain 
the survival benefit uniformly found in women. Our findings 
regarding treatment rates of nonsurgical treatment modali-
ties are in-line with previous studies. Lower treatment rates 
were found among older and more comorbid patients in two 
US studies. Age appeared to be a stronger negative factor for 
usage than comorbidity, and, as in our study, usage of chemo-
therapy in the oldest age category was very limited.14,15
Comorbidity as a prognostic factor has been exam-
ined in several previous publications. A Danish study based 
TABLE 4.  Receipt of Radiotherapy According to Treatment Intent, Adjusted for Case Mix
Curative Radiotherapy Palliative Radiotherapy
OR 95% CI OR 95% CI
Charlson score
  0 1.00 1.00
  1 0.95 0.78–1.15 1.07 0.96–1.18
  2 1.12 0.89–1.40 0.94 0.84–1.06
  3+ 1.51 1.12–2.02 1.05 0.90–1.21
  χ2 5.47 0.02 0.00 0.94
Multivariable logistic regression models are adjusted for age, sex, ECOG performance status, lung function (FEV
1
 %predicted), stage and histological type. χ2 for trend.
CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; FEV
1
, forced expiratory volume in 1 second; OR, odds ratio.
277Copyright © 2014 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 10, Number 2, February 2015 Role of Comorbidity on Lung Cancer Patient
on 1702 LC patients concluded that both overall and cancer-
specific mortality was increased in patients with CCI greater 
than equal to 3 (HR was 1.51 and 1.29, respectively).16 Another 
study found increased mortality for subgroups of patients with 
comorbidity and also found that the general increase in sur-
vival rates were less pronounced for patients with a high CCI.17
TABLE 5.  Survival among Nonresected Lung Cancer Patients According to Case Mix
Univariable Multivariable
HR 95% CI HR 95% CI
Charlson score
  0 1.00 1.00
  1 1.13 1.09–1.17 1.02 0.98–1.06
  2 1.20 1.16–1.25 1.06 1.02–1.10
  3+ 1.31 1.25–1.37 1.10 1.05–1.16
  χ2 174.26 <0.001 18.44 <0.001
Age (yr)
  <60 1.00 1.00
  60–69 1.08 1.03–1.12 1.07 1.03–1.12
  70–79 1.38 1.32–1.44 1.31 1.25–1.36
  80+ 1.78 1.69–1.87 1.53 1.45–1.61
  χ2 651.59 <0.001 340.31 <0.001
Sex
  Male 1.00 1.00
  Female 0.87 0.85–0.90 0.81 0.79–0.84
  χ2 87.30 <0.001 172.99 <0.001
PS
  0 1.00 1.00
  1 1.52 1.45–1.58 1.31 1.26–1.37
  2 2.11 2.01–2.21 1.75 1.67–1.84
  3 3.56 3.37–3.76 2.72 2.56–2.88
  4 6.54 6.10–7.02 4.65 4.31–5.01
  Unknown 2.08 1.98–2.18 1.96 1.83–2.09
  χ2 2518.12 <0.001 1459.91 <0.001
Histological type
  Adenocarcinoma 1.00 1.00
  Non-small cell 1.27 1.20–1.34 1.16 1.10–1.23
  Large cell 1.09 1.04–1.14 0.97 0.92–1.01
  Squamous cell 1.19 1.09–1.30 1.16 1.06–1.27
  Carcinoid 1.07 1.02–1.12 1.03 0.98–1.08
  Other specified 0.46 0.31–0.67 0.53 0.36–0.77
  Unspecified 1.01 0.81–1.26 1.07 0.86–1.34
  Unknown 1.36 1.31–1.41 1.10 1.06–1.15
  χ2 189.97 <0.001 63.48 <0.001
cTNM
  Ia 1.00 1.00
  Ib 1.51 1.34–1.69 1.51 1.34–1.69
  IIa 1.50 1.29–1.74 1.58 1.36–1.84
  IIb 2.13 1.88–2.42 2.08 1.84–2.36
  IIIa 2.19 1.98–2.44 2.25 2.02–2.50
  IIIb 2.79 2.51–3.10 2.88 2.59–3.20
  IV 4.09 3.70–4.52 4.01 3.63–4.44
  Unknown 3.23 2.91–3.59 2.18 1.94–2.45
  χ2 1988.84 <0.001 1848.89 <0.001
Multivariable models are adjusted for variables shown. χ2 for trend or heterogeneity, where appropriate.
CI, confidence interval; HR, hazard ratio; PS, performance status; cTNM, clinical tumor, lymph nodes and metastasis.
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As comorbidity is a prognostic factor, we need to ascer-
tain this for risk stratification of patients who are candidates 
for the treatment of LC. For surgical patients, a multivariable 
risk score system has been developed (Thoracoscore), with 
nine variables that may be a useful clinical tool for predict-
ing risk of death.18 Thoracoscore has been incorporated in the 
British Thoracic Society guidelines to evaluate the operative 
mortality risk of patients undergoing thoracic surgery.19 No 
similar instrument has been developed for nonsurgical LC 
patients.
An interesting feature about comorbidity is that we 
may have some influence over it in contrast to sex and age. If 
comorbidity was well controlled in LC patients, an improve-
ment in PS and the ability to tolerate treatment could be antici-
pated. Significant excess non-cancer mortality has been found 
in long-term LC survivors, and most likely this is caused by 
comorbidities.20 A study of comorbidity care found inconsis-
tent differences between cancer survivors and matched con-
trols; some patients (colorectal) received less comorbidity 
care while others (breast and prostate) received equivalent or 
more care than controls.21 It is likely that care for comorbid 
conditions is better for patients with a generally good prog-
nosis than for those with a poor prognosis. To address this 
problem, incorporation of comorbidity clinics in the oncology 
TABLE 6.  Survival among Nonresected Lung Cancer Patients Stratified by Treatment
Radiotherapy Chemotherapy Chemoradiation
Univariable Multivariable Univariable Multivariable Univariable Multivariable
HR 95% CI HR 95% CI HR 95% CI HR 95% CI HR 95% CI HR 95% CI
Charlson score
  0 1.00 1.00 1.00 1.00 1.00 1.00
  1 1.05 0.96–1.14 1.14 1.04–1.25 1.13 1.06–1.20 1.04 0.97–1.11 0.94 0.86–1.04 0.96 0.87–1.06
  2 0.97 0.88–1.07 1.10 1.00–1.21 1.19 1.10–1.28 1.08 1.00–1.16 1.01 0.89–1.15 0.95 0.84–1.08
  3+ 0.90 0.81–1.01 1.03 0.92–1.15 1.30 1.18–1.44 1.15 1.04–1.28 1.14 0.96–1.35 1.12 0.94–1.33
  χ2 2.91 0.09 1.47 0.23 44.09 <0.001 9.76 0.002 0.60 0.44 0.05 0.81
Age (yr)
  <60 1.00 1.00 1.00 1.00 1.00 1.00
  60–69 0.97 0.87–1.09 0.96 0.86–1.08 1.08 1.01–1.15 1.07 1.00–1.14 0.93 0.85–1.02 0.93 0.85–1.03
  70–79 0.93 0.83–1.03 1.05 0.94–1.18 1.34 1.25–1.44 1.24 1.15–1.33 1.12 1.01–1.24 1.18 1.06–1.31
  80+ 0.85 0.75–0.96 1.01 0.89–1.14 1.65 1.45–1.87 1.32 1.16–1.50 1.24 0.95–1.63 1.42 1.08–1.87
  χ2 9.17 0.003 0.76 0.38 106.13 <0.001 44.07 <0.001 5.47 0.02 11.74 <0.001
Sex
  Male 1.00 1.00 1.00 1.00 1.00 1.00
  Female 0.84 0.79–0.90 0.81 0.75–0.88 0.85 0.81–0.90 0.79 0.75–0.84 0.98 0.91–1.06 0.90 0.82–0.98
  χ2 23.07 <0.001 28.63 <0.001 37.65 <0.001 62.68 <0.001 0.30 0.58 6.12 0.01
PS
  0 1.00 1.00 1.00 1.00 1.00 1.00
  1 1.32 1.18–1.47 1.32 1.17–1.47 1.55 1.45–1.65 1.30 1.22–1.39 1.24 1.13–1.37 1.19 1.08–1.31
  2 1.60 1.42–1.81 1.56 1.38–1.77 1.97 1.81–2.14 1.55 1.42–1.69 1.49 1.32–1.69 1.39 1.22–1.58
  3 2.20 1.91–2.54 1.86 1.60–2.15 2.80 2.44–3.21 2.22 1.93–2.55 1.88 1.52–2.34 1.75 1.40–2.18
  4 3.01 2.38–3.80 2.51 1.97–3.19 3.92 2.80–5.48 2.86 2.03–4.01 2.49 1.47–4.22 2.09 1.22–3.61
  Unknown 1.65 1.46–1.86 1.32 1.11–1.58 1.57 1.45–1.69 1.31 1.15–1.49 1.27 1.13–1.43 1.14 0.94–1.38
  χ2 141.70 <0.001 94.11 <0.001 441.09 <0.001 189.79 <0.001 65.15 <0.001 43.33 <0.001
cTNM
  Ia 1.00 1.00 1.00 1.00 1.00 1.00
  Ib 1.87 1.45–2.41 1.87 1.46–2.41 1.29 0.99–1.68 1.17 0.90–1.53 1.08 0.71–1.65 1.07 0.70–1.63
  IIa 2.37 1.69–3.33 2.27 1.61–3.18 1.47 1.09–1.99 1.44 1.06–1.95 1.09 0.68–1.76 1.05 0.65–1.70
  IIb 2.97 2.25–3.91 3.04 2.30–4.01 1.98 1.49–2.63 1.87 1.40–2.49 1.31 0.86–2.00 1.22 0.80–1.86
  IIIa 2.90 2.30–3.65 2.81 2.23–3.55 2.58 2.03–3.29 2.27 1.78–2.89 1.18 0.81–1.72 1.14 0.78–1.67
  IIIb 3.52 2.78–4.46 3.59 2.82–4.56 3.75 2.95–4.77 3.15 2.48–4.02 1.57 1.08–2.29 1.58 1.08–2.30
  IV 5.38 4.32–6.69 5.36 4.29–6.69 5.02 3.97–6.35 4.16 3.28–5.26 2.54 1.76–3.68 2.41 1.66–3.50
  Unknown 3.99 3.20–4.99 3.66 2.84–4.73 3.87 3.04–4.92 2.89 2.22–3.76 1.89 1.30–2.76 1.78 1.18–2.66
  χ2 444.60 <0.001 388.16 <0.001 813.98 <0.001 651.46 <0.001 176.75 <0.001 155.89 <0.001
χ2 for trend or heterogeneity, where appropriate. Survival time is calculated from the start of treatment.
CI, confidence interval; cTNM, clinical tumor, lymph nodes and metastasis; HR, hazard ratio.
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wards, perhaps in conjunction with other measures directed at 
improving PS such as physical exercise and dietary instruc-
tion, could potentially improve survival.
We have no information as to the exact anticancer drug 
use on an individual basis. It is possible that treatments with 
a low grade of toxicities such as tyrosine kinase inhibitors 
may be used more extensively among older or more comorbid 
patients than chemotherapy.
CONCLUSION
Treatment rates are highly dependent on age and to a 
lesser extent on comorbidity. Several factors significantly 
affect outcome of cancer treatment, such as stage, PS, age, 
sex, and comorbidity. Of these factors, comorbidity appears 
to be weaker than PS. This has implications for the individ-
ual risk stratification of patients when selecting treatment. It 
also has implications for the generalization of findings from 
clinical trials where the high-risk populations for age, PS, and 
comorbidity routinely are excluded.
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